The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Isabelle Whitehead, a student at Ripon Grammar School, has earned a place to study medicine, inspired by the care given to ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

A young carer soon to be a future doctor as well as a Judo star in North Yorkshire are just two of thousands of students who received top ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $30.00, and a low estimate of $22.00. This upward trend is apparent, ...

HONG KONG SAR - Media OutReach Newswire - 8 August 2025 - Bora Pharmaceuticals (TWSE: 6472) today announced its financial ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...